ViewMind Applauded by Frost & Sullivan for Its One-of-a-Kind Digital Biomarker Technology for Neurocognitive Disorders

The AI-powered technology can enable early screening at scale for a range of neurocognitive conditions, such as Alzheimer's and mild cognitive impairment. SANTA CLARA, Calif., May 25, 2021 /CNW/ -- Based on its recent analysis of the global market for digital biomarkers for neurocognitive disorders, Frost & Sullivan recognizes ViewMind with the 2021 Global Enabling Technology Leadership Award. ViewMind's reliable, non-invasive, affordable, and accessible digital biomarker technology employs artificial intelligence (AI) to deliver accurate clinical results. The solution offers a standardized, non-invasive test that can detect the onset of diseases, such as Alzheimer's, up to an incredible 20 years before clinical symptoms appear. By enabling early treatment, this state-of-the-art technology is revolutionizing the digital biomarkers market.